Clinical trial
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT00096473 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00096473 |
|---|---|
| Title | Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease |
| Official title | A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia |
| Intervention type | Drug |
| Interventions | Donepezil hydrochloride |
| Enrollment | 229 |
| Start date | Jan 1, 2001 |
| Primary completion | Jun 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Nov 10, 2004 |
| Last update posted | Apr 1, 2011 |
| Countries | Australia, Canada, France, Ireland, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: